← Human Trials & Peer-Reviewed Studies
Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
Plain-language guide to PMID 42156721 (2026): double-blind randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 42156721
- Journal
- Nature communications
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Corley MJ et al. (7 authors)
- DOI
- 10.1038/s41467-026-72861-3
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in this randomized controlled trial publication.
To address this gap, the researchers profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures.
Why It Was Studied
Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking.
The researchers report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39).
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.
The Semaglutide group and the comparison group ran side by side rather than switching.
What Was Measured
The parent trial's primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified.
The subject headings attached to it are Aging, DNA Methylation, Epigenesis, Genetic, Glucagon-Like Peptides, HIV Infections and Semaglutide.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.
The publication is from 2026 (Nature communications), a journal based in England.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.